Find out why Bracco is the trusted partner in cardiac PET

Bracco is the industry leader in cardiac PET imaging with more than three million diagnostic studies to date. We have helped hundreds of world-class cardiac care facilities, hospitals and esteemed teaching institutions achieve enhanced diagnostic certainty, operational efficiency and safety in the diagnosis of coronary artery disease (CAD).

The Bracco Difference:

  • An extensive team of accessible, locally-based experts stand ready to support you and your staff.
  • Exclusive, customized business case tools help ensure you meet your financial goals.
  • Drive clinical and operational excellence in your organization with Bracco’s peer-to-peer support program.
  • Ongoing, complimentary clinical training at your facility keeps your staff at its best.
  • Bracco supports the business side of your practice with personalized reimbursement training and updates.

Bracco was the first company to drive the adoption of cardiac PET through innovation, research and development. Today, we are committed to growth and preservation of the modality for you and your patients.

About Bracco Imaging

Bracco Imaging S.p.A., part of the Bracco Group, is one of the world’s leading companies in the diagnostic imaging business. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures, and markets diagnostic imaging agents and solutions that meet medical needs.

Bracco Imaging offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray Imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers. The diagnostic imaging portfolio is completed by a range of medical devices and advanced administration systems for contrast imaging products.

The company operates in over 100 markets worldwide, either directly or indirectly, through subsidiaries, joint ventures, licenses, and distribution partnership agreements. With on-going research covering all key modalities, Bracco Imaging has a strong presence in key geographies: North America, Europe, and Japan operating through the Joint Venture Bracco-Eisai Co. Ltd. The Company also operates in Brazil, South Korea, and China through the Joint Venture Bracco Sine Pharmaceutical Corp. Ltd.

Operational investments have been made in order to achieve top quality, compliant, and sustainable eco-friendly production. Manufacturing activities are located in Italy, Switzerland, Japan, China, and Germany.

Bracco Imaging is an innovative Research and Development (R&D) structure with an efficient process-oriented approach and a track record of innovation in the diagnostic imaging industry. R&D activities are managed in the three Research Centers located in Italy, Switzerland, and the USA.

To learn more about Bracco Imaging, visit www.braccoimaging.com.

Indications and Usage:
CARDIOGEN-82® (Rubidium Rb 82 Generator) is a closed system used to produce Rubidium Rb 82 chloride injection for intravenous administration. Rubidium Rb 82 chloride injection is a radioactive diagnostic agent indicated for positron emission tomography (pet) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease.

IMPORTANT SAFETY INFORMATION:

Indications and Usage:
CARDIOGEN-82® (Rubidium Rb 82 Generator) is a closed system used to produce Rubidium Rb 82 chloride injection for intravenous administration. Rubidium Rb 82 chloride injection is a radioactive diagnostic agent indicated for positron emission tomography (pet) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease.

IMPORTANT SAFETY INFORMATION:

WARNING: HIGH LEVEL RADIATION EXPOSURE WITH USE OF INCORRECT ELUENT AND FAILURE TO FOLLOW THE ELUATE TESTING PROTOCOL
Please see full prescribing information for complete boxed warning

High Level Radiation Exposure with Use of Incorrect Eluent
Using the incorrect eluent can cause high Strontium (Sr) 82 and Sr 85 breakthrough levels (5.1)

  • Use only additive-free 0.9% Sodium Chloride Injection USP to elute the generator (2.4)
  • Immediately stop the patient infusion and permanently discontinue the use of the affected CardioGen-82® generator if the incorrect solution is used to elute the generator (4)
  • Evaluate the patient’s radiation absorbed dose and monitor for the effects of radiation to critical organs such as bone marrow (2.7)

Excess Radiation Exposure with Failure to Follow the Eluate Testing Protocol
Excess radiation exposure occurs when the levels of Sr 82 or Sr 85 in the Rubidium Rb 82 chloride injection exceed limits. (5.2)

  • Record eluate volume, including waste and test volumes (2.4)
  • Strictly adhere to the generator eluate testing protocol (2.5)
  • Stop using the generator if it reaches any of its Expiration Limits (2.6)

Please see full Prescribing Information for CardioGen-82® (Rubidium Rb 82 Generator) including boxed WARNING by clicking HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.

CardioGen-82 is manufactured for Bracco Diagnostics Inc., Monroe Township, NJ 08831, by GE Healthcare, Medi-Physics, Inc., South Plainfield, NJ 07080. 

We are Cardiac PET is a trademark of Bracco Diagnostics Inc.

CardioGen-82 is a registered trademark of Bracco Diagnostics Inc.